Amgen's Imdelltra Achieves Phase 3 Success in First-line SCLC and Enters Standard of Care

Amgen's (AMGN) DLL3-targeted bispecific T-cell engager (BiTE) Imdelltra (generic name tarlatamab) demonstrated improved overall survival (OS) in an early analysis of the Phase 3 clinical trial (DeLLphi-305) for first-line extensive-stage small cell lung cancer (ES-SCLC). In this trial evaluating combination therapy with AstraZeneca's (AZN) immunotherapy Imfinzi (durvalumab), progression-free survival (PFS) and objective response rate (ORR) also showed statistically significant improvements compared to monotherapy. Following its FDA accelerated approval as a 2nd-line treatment in May 2024 and generating approximately $627 million in revenue the previous year, Imdelltra is now positioned to directly target the $4.5 billion lung cancer standard-of-care market through this 1st-line setting success.

Karyopharm's Debt Repayment Deferral and Xpovio Approval Milestone

Karyopharm Therapeutics (KPTI) has extended the deadline for its $15.8 million maturing debt by approximately one month to October 15 through an agreement with creditors. The company secured a much-needed runway for restructuring and financing by paying lenders and bondholders $20 million worth of new convertible shares as a fee. Karyopharm is currently staking its survival on the FDA's decision regarding the supplemental New Drug Application (sNDA) for the addition of a myelofibrosis (MF) indication for its XPO1 inhibitor, Xpovio (selinexor).

Evommune and BridgeBio's Clinical Setbacks and Pipeline Restructuring

Evommune's (EVMN) oral MRGPRX2 inhibitor, EVO756, failed to meet its primary endpoint in a Phase 2 clinical trial for atopic dermatitis (AD), marking its second consecutive setback following a failure in chronic urticaria this past June. With over 40% of its market capitalization evaporated since its IPO, market attention is shifting toward the follow-up pipeline candidate EVO301, which targets patients refractory to Dupixent. Meanwhile, BridgeBio Oncology (BBOT) decided to discontinue its first-line lung cancer trial for the KRAS G12C inhibitor BBO-8520 to focus on second-line combination therapy, causing its stock price to plummet by more than 30%.

Selective Venture Investment Concentration in Gene Therapy and AI Platforms

Amidst a selective investment climate, CNS rare disease gene therapy company Encoded Therapeutics successfully secured $275 million in Series F funding. The capital, which included participation from GV and ARCH Venture Partners, will be focused on advancing the clinical development of its Dravet syndrome AAV9 gene therapy, ETX-101, and strengthening in-house manufacturing (GMP) capabilities. Additionally, Schrödinger (SDGR) launched Tectora with a $55 million Series A, signaling a full-scale entry into clinical trials for anti-inflammatory therapeutics based on its molecular design platform.